key: cord-0729697-6q86d4qd
authors: Cervia, Carlo; Nilsson, Jakob; Zurbuchen, Yves; Valaperti, Alan; Schreiner, Jens; Wolfensberger, Aline; Raeber, Miro E.; Adamo, Sarah; Weigang, Sebastian; Emmenegger, Marc; Hasler, Sara; Bosshard, Philipp P.; De Cecco, Elena; Bächli, Esther; Rudiger, Alain; Stüssi-Helbling, Melina; Huber, Lars C.; Zinkernagel, Annelies S.; Schaer, Dominik J.; Aguzzi, Adriano; Kochs, Georg; Held, Ulrike; Probst-Müller, Elsbeth; Rampini, Silvana K.; Boyman, Onur
title: Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
date: 2020-11-20
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2020.10.040
sha: 78e97b5282785e71d8b6cf7e499dba6ad5aee255
doc_id: 729697
cord_uid: 6q86d4qd

Background Whereas severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody tests are increasingly used to estimate the prevalence of SARS-CoV-2 infection, the determinants of these antibody responses remain unclear. Objectives To evaluate systemic and mucosal antibody responses toward SARS-CoV-2 in mild versus severe coronavirus disease 2019 (COVID-19) cases. Methods Using immunoassays specific for SARS-CoV-2 spike proteins, we determined SARS-CoV-2-specific immunoglobulin A (IgA) and immunoglobulin G (IgG) in sera and mucosal fluids of two cohorts, including SARS-CoV-2 polymerase chain reaction (PCR)+ patients (n = 64) as well as PCR+ and PCR– healthcare workers (n = 109). Results SARS-CoV-2-specific serum IgA titers in mild COVID-19 cases were often transiently positive, whereas serum IgG titers remained negative or became positive 12–14 days after symptom onset. Conversely, patients with severe COVID-19 showed a highly significant increase of SARS-CoV-2-specific serum IgA and IgG titers after symptom onset. Very high titers of SARS-CoV-2-specific serum IgA correlated with severe acute respiratory distress syndrome (ARDS). Interestingly, some healthcare workers with negative SARS-CoV-2-specific serum antibody titers showed SARS-CoV-2-specific IgA in mucosal fluids with virus-neutralizing capacity in some cases. SARS-CoV-2-specific IgA titers in nasal fluids inversely correlated with age. Conclusions Systemic antibody production against SARS-CoV-2 develops mainly in severe COVID-19, with very high IgA titers seen in patients with severe ARDS, whereas mild disease may be associated with transient production of SARS-CoV-2-specific antibodies but stimulate mucosal SARS-CoV-2-specific IgA secretion.

results showed a specificity for anti-S1 IgA of >95% and anti-S1 IgG >99%, which is 197 in accordance with recently published data. 29 Furthermore, we assessed the samples of the HCW mucosal subgroup using an in-203 house immunoassay for IgA and IgG against S protein extracellular domain (ECD), 204 RBD, and NC. 30 Mucosal samples were pre-diluted 1:2 in sample buffer (PBS Tween-205 20 0.1%, 1% milk) and serum was pre-diluted 1:20 in sample buffer and transferred to 206 antigen-coated 1536-well assay plates using acoustic dispensing technology (Labcyte 207 ECHO 555) with serial dilutions ranging from 1:5-1:640 (mucosal samples) and 208 1:50-1:6400 (serum). ODs were measured at 450 nm in a multimode plate reader 209

Descriptive statistics for the cohort of patients (stratified by mild versus severe 237 disease) and the HCW cohort are presented as median and interquartile ranges for 238 continuous variables, as well as numbers and percentages of total for categorical 239 variables. For the comparison of location parameters in two independent groups, the 240 Wilcoxon's rank sum test was used, in a version accounting for ties. 31 For the 241 comparison of more than two independent groups, the non-parametric Kruskal-Wallis 242 test was used. Multiple linear regression models were used to quantify the association 243 between log-transformed IgA and IgG titers as outcomes as well as a set of pre-244 defined independent variables. These included disease severity, age, duration of 245 symptoms (days), and patient comorbidities. Generalized additive models were used 246 to evaluate potential non-linear relationships of disease duration with the two 247 outcomes, as described above. Wilcoxon test was used to test for differences between 248 two continuous variables in the tables, and P values were adjusted using the Holm 249 method. Fisher's exact test was used for comparing two and Chi-square for comparing 250 three categorical variables. Non-parametric Spearman correlations were used for the 251 comparison between different immunoassays. 252

Statistical analyses were performed with R (version 3.6.1) and using the packages 253 "coin" and "mgcv". Graph-Pad Prism was used for visualization. P values in the 254 patient cohort were adjusted for multiple testing, using the method proposed by 255

Benjamini-Hochberg. 32 Adjusted P values were considered statistically significant if 256 smaller than the significance level of α = 0.05. In the HCW mucosal subgroup, 257 evidence was quantified on a continuous scale and these results were considered 258 exploratory. (Table 1) were assessed for IgA and IgG antibodies toward the SARS-CoV-265 2 S1 protein by using highly-specific immunoassays. The mean period between 266 reported symptom onset and serum collection were 13.5 days (median 9 days) in the 267 mild COVID-19 group and 20.2 days (median 15.5 days) in the severe COVID-19 268 group of patients, respectively ( Figure E1A ). In comparison to mild COVID-19, 269 patients with severe disease had on average higher serum titers of S1-specific IgA (P 270 < 0.0001) and IgG (P < 0.0001) ( Figure 1A) . In mild COVID-19 cases, serum titers 271 of S1-specific IgA increased slightly (P < 0.0001) as a function of time from serum 272 sampling to symptom onset ( Figure 1B) . Likewise, serum titers of S1-specific IgG 273 increased moderately (P = 0.002) in mild cases ( Figure 1B) . These antibody 274 responses revealed no significant pattern associated with patient age (P = 0.15 for 275

IgA, and P = 0.28 for IgG) (Figure 1C) , sex ( Figure E1B and E1C), pre-existing 276 comorbidities, including hypertension, diabetes mellitus, heart disease, 277 cerebrovascular disease, lung disease, and kidney disease, or immunosuppressive 278 treatment. In patients with a history of solid cancer, lower S1-specific IgA titers were 279 detectable ( Table 2) . 280

On average, positive S1-specific serum IgA titers became evident in mild COVID-19 281 cases ten days after symptom onset ( Figure 1B) . S1-specific serum IgA titers peaked 282 in samples drawn at around three weeks from symptom onset, whereas in subjects 283 tested later S1-specific serum IgA tended to be lower. As for S1-specific serum IgG 284 patients around 12-14 days after symptom onset ( Figure 1B) . 286

In stark contrast to mild cases, patients suffering from severe COVID-19 showed a 287 strong correlation of serum titers of S1-specific IgA with disease duration (P = 288 0.0008), which was even more pronounced for serum titers of S1-specific IgG (P < 289 0.0001) ( Figure 1B) . These antibody responses became positive on average in 290 samples obtained on day 3-4 for IgA and day 4-5 for IgG, and they appeared to be 291 independent of patient age (P = 0.76 for IgA, and P = 0.76 for IgG), sex, and 292 comorbidities ( Figure 1B and 1C, Figure E1B and E1C, and Table 2) . 293

When grouped according to level of care, we observed in mild cases of COVID-19 294 that S1-specific serum IgA titers did not show any discernible pattern, whereas S1-295 specific serum IgG titers were higher in hospitalized compared to outpatient cases 296 ( Figure 2A) . Thus, we next assessed disease severity and, as expected, younger 297 patients tended to have milder disease, whereas older patients had more severe 298 manifestations ( Figure E2 ). There was no time-dependent pattern visible for S1-299 specific serum IgA, whereas S1-specific serum IgG titers showed a stronger increase 300 over time in mild pneumonia cases versus those with mild illness ( Figure 2B ). 301 Strikingly, very high titers (>25 optical density [OD] ratio) of SARS-CoV-2-specific 302 serum IgA, but not serum IgG, correlated with severe ARDS (Figure 2B and Figure  303 E3). In a multiple linear model on all patients, there was strong evidence for an 304 association between severe disease, days after symptom onset and increased S1-305 specific serum IgA and IgG responses. Immunosuppressive therapy was not 306 associated with decreased S1-specific serum IgG titers ( Table 2) . 307

In summary, disease severity appears to influence S1-specific serum IgA and IgG 308 titers and S1-specific IgA responses might occur transiently in patients with mild 309 disease. To evaluate this latter hypothesis, we conducted a longitudinal study in two 310 selected patients with mild COVID-19, as presented below. 311

We followed up two adults (a 42-year old woman and a 42-year old man, living 313 together as a couple) with mild, RT-qPCR-confirmed SARS-CoV-2 infection. He 314 (patient COV2-A0013) developed fatigue and cough from day 0 on, followed by fever 315 on day 1, and dysosmia on days 9-16. She (patient COV2-A0014) showed signs of 316 fatigue and sore throat from day 0 on, fever between days 2-5, and cough on day 3 317 ( Figure 3A) . 318

The RT-qPCR cycle threshold (Ct) values at detection were low on days 1-20 for 319 patient COV2-A0013 and day 7 for patient COV2-A0014, indicating the presence of 320 high amounts of SARS-CoV-2 RNA in their nasal swabs ( Figure 3B ). On day 30 for 321 patient COV2-A0013 and from day 17 on for patient COV2-A0014, the Ct values 322 increased to 40 and more, thus indicating that the amount of virus RNA had dropped 323 below the detection limit ( Figure 3B) . 324 Patient COV2-A0013 showed S1-specific serum IgA titers that were negative on day 325 7, rose to borderline values on day 10, became positive on day 14 at a titer of 3.8 OD 326 ratio where they remained on day 20, and further increased to a titer of 8.5 OD ratio 327 on day 30; his S1-specific serum IgG titers remained negative on days 7-14, became 328 borderline positive on day 20, and clearly positive at an OD ratio of 4.5 on day 30 329 ( Figure 3C) . Conversely, S1-specific serum IgA titers in patient COV2-A0014 were 330 borderline on day 4, became positive on days 7 and 11, followed by a drop to 331 borderline values on days 17 and 28; her S1-specific serum IgG titers were negative 332 on days 4-7, became borderline on day 11 and weakly positive at an OD ratio of 1.1 333 on day 17, and remained weakly positive at an OD ratio of 1.8 on day 28 ( Figure 3C) . We compared these results to longitudinal analyses of S1-specific serum IgA and IgG 335 values in two different situations. In asymptomatic controls, S1-specific serum IgA 336 and IgG remained negative throughout the period of assessment, whereas in severe 337 COVID-19 cases both antibody responses increased after day 4-5 and were markedly 338 elevated on day 14-15 ( Figure E4) . 339

These longitudinal data in mild COVID-19 cases demonstrate that S1-specific serum 340

IgA production can be transient, whereas S1-specific serum IgG production occurs 341 late and correlates with the severity of clinical symptoms. 342 343 Some seronegative HCWs show SARS-CoV-2-specific IgA at mucosal sites. 344

Having observed that in mild COVID-19 cases, S1-specific serum IgA and IgG 345 production can be transient, delayed or even absent, we assessed serum S1-specific 346 antibody responses in a well-defined cohort of HCWs (n = 109; termed HCW cohort). with 8 out of 21 (38%) subjects having positive IgA and IgG titers for S1 of SARS-359

CoV-2 at the time of sampling ( Figure 5A) . 360

To investigate S1-specific IgA and IgG titers at mucosal sites, we analyzed tears, 361 nasal fluids, and saliva in a subset of the HCW cohort, termed HCW mucosal 362 subgroup (Figure 4 ). This subgroup also recorded self-reported clinical symptoms 363 (Table 3) . When assessing the Symp/PCR+ members of the HCW mucosal subgroup, 364 a clear correlation was evident between positivity of S1-specific IgA and IgG in 365 serum ( Figure 5B ) with the corresponding values in nasal secretions ( Figure 5C) . 366

Thus, for S1-specific IgG, Symp/PCR+ members with positive serum titers also 367 showed elevated titers of S1-specific IgG in nasal secretions ( Figure 5B and 5C) , 368 possibly indicating transfer of S1-specific IgG from serum to the nasal mucosa. 369

Conversely, the relationship of serum versus nasal fluid in Symp/PCR+ members was 370 more variable for S1-specific IgA (Figure 5B and 5C) . 371

To further investigate these findings, we adapted and used our two SARS-CoV-2 S 372 protein-specific immunoassays (Figure E5 and E6) to assess the subjects in the HCW 373 mucosal subgroup that tested negative for SARS-CoV-2-specific IgA or IgG in serum. 374

Firstly, we ruled out an influence of time of sampling or total amount of detectable 375

IgA and IgG in our samples. Mean time of sampling since symptom onset was 26.5 376 days for both Symp/PCR-and Symp/PCR+ groups of the HCW mucosal subgroup, 377

whereas the Asymp/PCR-group was tested 11 days or more after exposure. Total IgA 378

and IgG titers were comparable in serum samples as well as tear, nasal fluid, and 379 saliva samples of all three groups of participants ( Figure E7) . Notably, whereas total 380 IgG titers were measurable in nasal fluids, they were very low in tear fluid and saliva 381 ( Figure E7 ). Analyzing S protein-specific IgA and IgG in our mucosal samples, we 382 observed a reliable correlation between our two immunoassays for serum IgA and 383 J o u r n a l P r e -p r o o f Cervia et al. 18 IgG, as well as tear and nasal fluid IgA, whereas the other measurements were less 384 consistent and were thus not considered for our conclusions (Figure E6) . 385

Interestingly, we were able to detect S protein-specific IgA in the mucosal samples of 386 several subjects in the absence of seropositivity. Analyzing individual participants, we 387 found that subjects COV2-M0033, COV2-M0061, and COV2-M0103 showed high 388 S1-specific, ECD-specific, and RBD-specific IgA values in their nasal fluids, whereas 389

total IgA values were average in nasal fluids of these individuals (Figure 5D-5F and 390 Figure E7) . Moreover, the nasal fluid of subject COV2-M0015 contained high S1-391 specific and RBD-specific IgA values, in the presence of average total IgA values 392 ( Figure 5D-5F and Figure E7 ). When measuring tear fluid, subjects COV2-M0015 393 and COV2-M0033 presented with high S1-specific, ECD-specific, or RBD-specific 394

IgA values (Figure 5G-5I) . Additionally, a few other individuals also had detectable 395 S protein-specific IgG in their nasal fluid despite being IgG seronegative (Figure 5D -396 5F). Notably, some mucosal samples showed comparable neutralizing capacity to 397 serum in an in vitro neutralization assay of viable SARS-CoV-2 ( Figure E8) . These 398 findings further supported our detection of humoral immune reponses at mucosal sites 399 in mild COVID-19 cases in the absence of serum antibodies toward SARS-CoV-2. 400

In contrast to total IgA titers, assessing S protein-specific IgA values in nasal fluid 401 versus age in seronegative HCWs, we found an inverse correlation (R2adj = 0.153, P 402 = 0.037). The same analysis with S protein-specific IgA titers in serum versus age, 403 however, did not reveal a correlation (P = 0.58) (Figure 5J-5L) Collectively, in 15-20% of S protein-seronegative individuals in our cohort, we 408 detected S protein-specific IgA antibodies at several mucosal sites. Furthermore, 409 mucosal S protein-specific IgA titers inversely correlated with patient age, suggesting 410 increased mucosal antibody responses in younger SARS-CoV-2-exposed individuals. 411

In severe cases of COVID-19, we found that SARS-CoV-2 S protein-specific serum 413

IgA and IgG titers became positive in samples obtained on average 3-5 days after 414 symptom onset, which is in agreement with earlier publications. 16 

Validation of a commercially available SARS-CoV-2 serological immunoassay

Early peak and rapid decline of SARS-CoV-2 seroprevalence in a 623 Swiss metropolitan region

Quick and Easy Implementation of the 628

Procedure for Controlling the False Positive Rate in 629

Multiple Comparisons

Viral dynamics in 631 mild and severe cases of COVID-19

Clinical course and risk factors 633 for mortality of adult inpatients with COVID-19 in Wuhan, China: a 634 retrospective cohort study

Human immune system variation

Examination 638 of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA

and neutralization assay against viral spike pseudotyped virus

The role of senescent cells in ageing

Successful and Maladaptive T Cell Aging

Pre-646 existing and de novo humoral immunity to SARS-CoV-2 in humans

Anti-spike IgG causes 649 severe acute lung injury by skewing macrophage responses during acute SARS-650

The trinity of COVID-19: 652 immunity, inflammation and intervention

Distinct features of SARS-654

CoV-2-specific IgA response in COVID-19 patients

Ill Patients With COVID-19 With Convalescent Plasma

Lymphopenia-induced T cell proliferation is a hallmark of severe COVID-19

Dashed lines indicate borders between positive (red), borderline (gray) and 723 negative (blue) values, with gray shaded area showing borderline values. (B-C) S 724 protein-specific IgA (top) and IgG (bottom) serum (B) and nasal fluid (C) titers of 725

Symp/PCR+ individuals (n = 11) in HCW mucosal subgroup. Comparison of HCWs 726 with negative, borderline, and positive values. (D-F) S protein-specific IgA (top) and

SARS-CoV-2 S protein 728 extracellular domain (ECD)-specific (E), and S1 protein receptor-binding domain 729 (RBD)-specific IgA and IgG (F) of S1 protein-seronegative individuals in HCW 730 mucosal subgroup

HCWs with negative S protein-specific IgA serum values are labeled 732 individually. (G-I) S protein-specific IgA (top) and IgG (bottom) titers in tear fluid

ECD-specific (H), and RBD-specific IgA and IgG (I) of S1 734 protein-seronegative individuals in HCW mucosal subgroup

of S1 protein-specific IgA titers in serum (J), nasal fluids (K), and total IgA in nasal 736 fluids (L), as a function of age in S1 protein-seronegative individuals of HCW 737 mucosal subgroup